Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CTX-120 by CRISPR Therapeutics for Refractory Multiple Myeloma: Likelihood of Approval
CTX-120 is under clinical development by CRISPR Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData,...
Data Insights
CTX-120 by CRISPR Therapeutics for Relapsed Multiple Myeloma: Likelihood of Approval
CTX-120 is under clinical development by CRISPR Therapeutics and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData,...